Who are the top shareholders of the Sanjiv.Parant.?

The top shareholders of Sanjiv.Parant. are Ashwani Khemka with 27.13%, and Suresh Pukhraj Jain, the highest public shareholder, with 6.63%. Individual investors hold a combined 52.43%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Sanjiv.Parant. include Ashwani Khemka, who holds the largest share at 27.13%. The highest public shareholder is Suresh Pukhraj Jain, with a holding of 6.63%. Additionally, individual investors collectively hold 52.43% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

how big is Sanjiv.Parant.?

As of March 2024, Sanjivani Paranteral Ltd has a market capitalization of 297.00 Cr, with net sales of 66.52 Cr and net profit of 7.65 Cr over the latest four quarters. Shareholder's funds are valued at 27.90 Cr, and total assets amount to 43.41 Cr.

Market Cap: Sanjivani Paranteral Ltd has a market capitalization of 297.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 66.52 Cr, and the sum of Net Profit for the latest 4 quarters is 7.65 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. Shareholder's Funds are valued at 27.90 Cr, and Total Assets amount to 43.41 Cr.

Who are in the management team of Sanjiv.Parant.?

As of March 2022, the management team of Sanjiv.Parant. includes Ashwin Khemka (Chairman & Managing Director), Mrunmai M Sarvankar, Shrenikkumar P Solanki, and Monika Singhania (all Independent Directors), Srivardhan Ashwani Khemka (Director), and Ritu Puglia (Company Secretary & Compliance Officer).

As of March 2022, the management team of Sanjiv.Parant. includes the following individuals:<BR><BR>1. Ashwin Khemka - Chairman & Managing Director<BR>2. Mrunmai M Sarvankar - Independent Director<BR>3. Shrenikkumar P Solanki - Independent Director<BR>4. Monika Singhania - Independent Director<BR>5. Srivardhan Ashwani Khemka - Director<BR>6. Ritu Puglia - Company Secretary & Compliance Officer<BR><BR>These members play various roles in overseeing the company's operations and governance.

What does Sanjiv.Parant. do?

Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company focused on manufacturing injectables and oral solids, with a market cap of Rs 297 Cr and reported net sales of 18 Cr and net profit of 2 Cr for the quarter ending March 2025.

Overview: <BR>Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company specializing in the manufacturing of injectables and oral solids, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>History: <BR>Sanjivani Paranteral Ltd was incorporated as a public limited company in October. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 18 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 297 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.11 <BR>Return on Equity: 21.32% <BR>Price to Book: 7.71 <BR><BR>Contact Details: <BR>Address: 205 P N Khotari Indl Estate, LBS Marg Bhandup (West) Mumbai Maharashtra : 400078 <BR>Tel: 91-22-67290900 <BR>Email: info@sanjivani.co.in <BR>Website: http://www.sanjivani.co.in

Has Sanjiv.Parant. declared dividend?

No Dividend History Available

Who are the peers of the Sanjiv.Parant.?

Sanjiv.Parant.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ambalal Sarabhai, Coral Labs, Kimia Bioscien, and Sat Kartar. Notably, Sanjiv.Parant. has excellent management and growth, with a 1-year return of 33.70%.

Peers: The peers of Sanjiv.Parant. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ambalal Sarabhai, Coral Labs., Kimia Bioscien., Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Sanjiv.Parant., while Below Average management risk is found at Ambalal Sarabhai, Coral Labs., Kimia Bioscien., and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanjiv.Parant., while Below Average growth is noted for Divi's Lab., Torrent Pharma, Ambalal Sarabhai, and Kimia Bioscien. Average capital structure is found at Sanjiv.Parant., while Excellent capital structure is observed at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, and Good capital structure is noted for Torrent Pharma and Ambalal Sarabhai.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ambalal Sarabhai has the lowest at -21.20%. Sanjiv.Parant.'s 1-year return of 33.70% is higher than Ambalal Sarabhai's but lower than Divi's Lab.'s. Additionally, the six-month returns for Ambalal Sarabhai, Coral Labs., and Kimia Bioscien. are negative.

What is the technical trend for Sanjiv.Parant.?

As of May 28, 2025, the technical outlook for Sanjiv.Parant. is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands, and a year-to-date decline of 36.13% compared to the Sensex's gain of 5.48%.

As of 28 May 2025, the technical trend for Sanjiv.Parant. has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages also reflect a mildly bearish stance. Bollinger Bands show a mildly bearish trend on the weekly chart but are bullish on the monthly chart, suggesting mixed signals across time frames. The KST is bearish weekly and mildly bearish monthly, further supporting the overall mildly bearish outlook. The stock has underperformed the Sensex in the year-to-date period, with a significant decline of 36.13%, contrasting with the Sensex's gain of 5.48%. Overall, the current technical stance is mildly bearish, with key indicators such as MACD and moving averages driving this view.

Are Sanjiv.Parant. latest results good or bad?

Sanjivani Paranteral's latest results show mixed performance: while net sales and profit after tax have increased year-on-year, there was a decline in both net sales and net profit in the latest quarter, indicating potential concerns about profitability and debt management. Overall, the results lean more towards negative due to the recent quarterly downturn.

The latest results for Sanjivani Paranteral indicate a mixed performance. On one hand, the company has shown positive growth in net sales, achieving Rs 36.07 crore over the past six months, which is a year-on-year increase of 23.11%. Additionally, the profit after tax for the nine-month period has risen by 25.97%, reaching Rs 5.82 crore.<BR><BR>However, there are significant concerns as well. The company's quarterly performance for June 2025 revealed a decline in both net sales and net profit compared to the previous quarter, with net sales dropping by 1.60% and net profit decreasing by 21.00%. The earnings per share (EPS) also fell to Rs 1.46, the lowest in five quarters, reflecting reduced profitability for shareholders. Furthermore, the debtors turnover ratio has decreased, indicating a slowdown in the company's ability to manage its debts effectively.<BR><BR>Overall, while there are some positive growth indicators, the decline in quarterly performance and profitability suggests that the results could be viewed as more negative than positive.

When is the next results date for Sanjiv.Parant.?

The next results date for Sanjiv.Parant. is 14 November 2025.

The next results date for Sanjiv.Parant. is scheduled for 14 November 2025.

How has been the historical performance of Sanjiv.Parant.?

Sanjiv.Parant. experienced significant growth from March 2024 to March 2025, with net sales rising to 70.10 Cr from 54.41 Cr, and profit after tax increasing to 8.09 Cr from 6.17 Cr. The company also saw improvements in operating profit and cash flow from operating activities, alongside a rise in total assets and liabilities.

Answer:<BR>The historical performance of Sanjiv.Parant. shows significant growth from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Sanjiv.Parant. reported net sales of 70.10 Cr, an increase from 54.41 Cr in the previous year. Total operating income also rose to 70.10 Cr from 54.41 Cr, while total expenditure increased to 59.75 Cr from 46.17 Cr. The operating profit (PBDIT) grew to 11.57 Cr from 8.76 Cr, reflecting a healthy operating profit margin of 14.76%, slightly down from 15.14%. Profit before tax reached 10.35 Cr, up from 7.57 Cr, leading to a profit after tax of 8.09 Cr compared to 6.17 Cr the prior year. The earnings per share improved to 6.81 from 5.28. On the balance sheet, total assets increased to 78.20 Cr from 43.41 Cr, with total liabilities also rising to 78.20 Cr from 43.41 Cr. Cash flow from operating activities improved to 12.00 Cr from -10.00 Cr, while cash flow from investing activities worsened to -21.00 Cr from -12.00 Cr. Overall, the company demonstrated strong growth in sales and profitability, alongside a notable increase in total assets and liabilities.

Should I buy, sell or hold Sanjiv.Parant.?

Is Sanjiv.Parant. overvalued or undervalued?

As of November 17, 2025, Sanjiv.Parant. is considered very expensive and overvalued due to its high PE ratio of 30.96, price to book value of 6.08, and EV to EBITDA of 23.36, especially in light of its 37.72% decline in stock performance compared to the Sensex's 9.50% gain over the past year.

As of 17 November 2025, the valuation grade for Sanjiv.Parant. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued based on its high PE ratio of 30.96, a price to book value of 6.08, and an EV to EBITDA of 23.36. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.69, while Cipla appears more attractive with a PE of 22.81.<BR><BR>Given these ratios and the overall market context, Sanjiv.Parant.'s valuation seems excessive, particularly when considering its recent stock performance, which has underperformed the Sensex significantly over the past year, with a decline of 37.72% compared to the Sensex's gain of 9.50%. This further reinforces the conclusion that the company is overvalued in its current state.

Why is Sanjiv.Parant. falling/rising?

As of 03-Dec, Sanjivani Paranteral Ltd's stock price is at 198.10, down 0.35%. The stock has shown strong weekly performance but has a year-to-date decline of 48.14%, indicating potential long-term bearish trends despite increased investor interest.

As of 03-Dec, Sanjivani Paranteral Ltd's stock price is currently at 198.10, reflecting a decrease of 0.7, or 0.35%. The stock has experienced a trend reversal, having fallen after five consecutive days of gains. This recent decline may be attributed to its performance today, where it underperformed its sector by 0.34%. <BR><BR>Despite the recent drop, the stock has shown strong performance over the past week, with a return of 8.02%, while the benchmark Sensex has declined by 0.59%. However, over the longer term, the stock has faced significant challenges, with a year-to-date decline of 48.14% compared to the Sensex's gain of 8.92%. <BR><BR>Additionally, while the stock's current price is higher than its 5-day and 20-day moving averages, it remains lower than the 50-day, 100-day, and 200-day moving averages, indicating a potential bearish trend in the longer term. On a positive note, there has been a rise in investor participation, with delivery volume increasing by 81.55% against the 5-day average, suggesting some interest from investors despite the current price decline.

Which are the latest news on Sanjiv.Parant.?